Myriad’s Expanded Aneuploidy Analysis Could Improve Birth Outcomes
Enhanced test improves detection of chromosomal abnormalities by 30%.
Read MorePosted by Chaunie Brusie | Feb 14, 2019 | Womens Health |
Enhanced test improves detection of chromosomal abnormalities by 30%.
Read MorePosted by Steve Halasey | Feb 8, 2019 | Cancer |
To improve cancer care, laboratory stakeholders are urging CMS to revise its policy decision on next-generation sequencing.
Read MorePosted by Chaunie Brusie | Feb 5, 2019 | Culture Media, Leukemia |
Clearance enables accurate and easy-to-interpret AML and MDS detection with reduced validation burden.
Read MorePosted by Steve Halasey | Jan 31, 2019 | Electrolytes, Heart Disease, Lab Automation |
The current generation of instruments for in vitro diagnostics is helping to support clinical labs through a strong emphasis on automation.
Read MorePosted by Steve Halasey | Jan 31, 2019 | Company News, Research |
Baby Genes will continue to operate as a wholly-owned subsidiary under the name ArcherDx Clinical Services Inc, and the company will continue to market the suite of existing newborn and carrier screening genetic testing services under the Baby Genes brand name.
Read More